| 0.3936 0 (0%) | 11-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company focused on developing innovative genetic therapies aimed at transforming the lives of patients battling rare and debilitating diseases. Its advanced product portfolio includes three ophthalmology development programs addressing two specific targets. These encompass treatments for X-linked retinitis pigmentosa and achromatopsia, both currently undergoing Phase 1/2 clinical trials. Additionally, an optogenetic therapy candidate is in development to tackle advanced retinal conditions. Beyond its ophthalmic initiatives, AGTC is advancing several preclinical programs. These early-stage endeavors include a program for otology (ear disorders), another for dry age-related macular degeneration, and two targeting central nervous system disorders like frontotemporal dementia and amyotrophic lateral sclerosis. The company maintains strategic partnerships with entities such as the University of Florida, Bionic Sight, Inc., and Otonomy, Inc. Founded in 1999, AGTC's operations are based out of its headquarters in Alachua, Florida.
Thu, 24 Apr 2025
AGTC Stock Price, News & Analysis - Stock Titan
Thu, 30 Jan 2025
Advancing Rare Disease Clinical Trials With Point-Of-Need Eye Assessments - Clinical Leader
Tue, 13 Jun 2023
Syncona launches ophthalmic gene therapy venture Beacon Therapeutics - Ophthalmology Times Europe
Tue, 13 Jun 2023
Beacon Therapeutics enters gene therapy arena with $120m launch - Pharmaceutical Technology
Mon, 14 Nov 2022
Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022 - Yahoo Finance
Tue, 25 Oct 2022
Syncona to acquire struggling AGTC for $23.5 million - pharmaphorum
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|